Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)
- Conditions
- Congenital, Familial and Genetic DisordersNeoplasm, Breast
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Borstkanker Onderzoek Groep
- Target Recruit Count
- 130
- Registration Number
- NCT05392608
- Locations
- 🇳🇱
Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands
🇳🇱Noordwest Ziekenhuisgroep, Alkmaar, Netherlands
🇳🇱Ziekenhuis Amstelland, Amstelveen, Netherlands
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Tvardi Therapeutics, Incorporated
- Target Recruit Count
- 6
- Registration Number
- NCT05384119
- Locations
- 🇺🇸
Holy Cross Health Fort Lauderdale - Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
- Conditions
- HR-positive, HER2-negative Breast Neoplasms
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 432
- Registration Number
- NCT05365178
- Locations
- 🇨🇳
The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05328440
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
- Conditions
- Metastatic HER2-Positive Breast CarcinomaPrognostic Stage IB Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8
- Interventions
- Other: Quality-of-Life Assessment
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT05319873
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Conditions
- Breast Cancer
- Interventions
- Drug: Anastrozole, Exemestane, or Letrozole
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT05307705
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇩🇪Universitätsklinikum Erlangen, Erlangen, Bayern, Germany
🇺🇸Mayo Clinic of Scottsdale, Scottsdale, Arizona, United States
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05306340
- Locations
- 🇯🇵
Nagoya University Hospital, Aichi, Japan
🇿🇦Medical Oncology Centre of Rosebank, Johannesburg, South Africa
🇪🇸Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, LA Coruna, Spain
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
- Conditions
- ER-Positive Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 28
- Registration Number
- NCT05305924
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
- Conditions
- Breast CancerSolid Tumors
- Interventions
- Drug: PF-07220060 + PF-07104091 combination dose escalation
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT05262400
- Locations
- 🇺🇸
Administrative Address: UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
(VELA) Study of BLU-222 in Advanced Solid Tumors
- Conditions
- HR+ Breast CancerCarcinosarcomaAdvanced Solid TumorsCCNE1 AmplificationHER2-negative Breast CancerGastric CancerEsophageal AdenocarcinomaOvarian CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 366
- Registration Number
- NCT05252416
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Stanford Women's Cancer Center, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.